Psychedelic drugs are a class of substances that alter perception, mood, and thought by acting on serotonin pathways in the brain. They include both naturally occurring compounds found in mushrooms, plants, and even animal species, as well as synthetic molecules created in laboratories. While most remain federally illegal in the United States, they’ve become the focus of serious clinical research for conditions like depression and PTSD.
How Psychedelics Work in the Brain
Classic psychedelics, including LSD, psilocybin, and DMT, produce their effects primarily by activating serotonin 2A receptors on nerve cells in the brain’s cortex. What makes these drugs unusual is where they do this. Unlike serotonin itself, which can only activate receptors on the outer surface of a cell, psychedelic molecules are able to slip through cell membranes and activate receptors inside the cell. This difference in location appears to be what triggers the dramatic shifts in perception and mood that define the psychedelic experience.
Once those receptors are activated, several things happen in quick succession. The brain’s normal patterns of synchronized activity start to break down. Regions that don’t usually communicate begin sharing information, while networks that typically work in tight coordination become less organized. Brain imaging studies consistently show that psychedelics decrease connectivity within the Default Mode Network, a group of brain regions responsible for your sense of self, mental time travel, and the ongoing internal monologue most people experience. At the same time, connections between normally separate brain networks increase. The result is a brain state that’s more flexible, less self-focused, and less constrained by habitual patterns of thought.
This disruption of the Default Mode Network is the leading explanation for one of the most distinctive psychedelic effects: ego dissolution, the feeling that the boundary between yourself and the world has temporarily dissolved. Researchers describe this as a loosening of the brain’s prior beliefs about reality, which may allow rigidly held thought patterns to be revised.
Types of Psychedelic Drugs
The term “psychedelic” is sometimes used loosely, but pharmacologically these substances fall into distinct categories based on how they interact with the brain.
Classic psychedelics all work through serotonin receptors. This group includes LSD (a synthetic compound), psilocybin (found in over 200 species of mushrooms across several genera), DMT (a key ingredient in the Amazonian brew ayahuasca, also found in certain grasses, legumes, and even marine sponges and frogs), and mescaline (found in peyote and San Pedro cacti). These substances produce vivid changes in visual perception, emotional intensity, and a sense that ordinary reality has shifted in fundamental ways.
Dissociative drugs like ketamine, PCP, and dextromethorphan (DXM) work through an entirely different system. They block glutamate receptors, the brain’s primary excitatory signaling system. Rather than intensifying sensory experience the way classic psychedelics do, dissociatives produce a feeling of detachment from your body and surroundings, often described as floating or watching yourself from the outside. Salvia divinorum is sometimes grouped with dissociatives but works through yet another mechanism, activating a specific type of opioid receptor.
Empathogens like MDMA (commonly known as ecstasy or molly) increase feelings of emotional closeness, trust, and empathy. MDMA primarily floods the brain with serotonin, dopamine, and norepinephrine rather than directly activating serotonin 2A receptors, which is why its effects feel distinct from a classic psychedelic trip.
What Psychedelics Do to Brain Structure
Beyond the temporary experience, psychedelics appear to physically remodel the brain’s wiring. Within hours of exposure, these compounds trigger rapid growth of dendritic spines, the tiny protrusions on nerve cells where connections to other neurons form. They also increase the complexity of dendritic branches (the tree-like extensions neurons use to receive signals) and boost levels of a key growth-promoting protein called BDNF. This protein supports the survival of existing neurons, encourages new connections, and helps stabilize circuits after they’ve been reshaped.
These changes are significant enough that researchers have coined a term for substances that produce them: psychoplastogens. The neuroplasticity effects may also explain why single doses of psychedelics can produce psychological changes lasting weeks or months. Some evidence suggests psychedelics temporarily reopen windows of heightened brain flexibility similar to the critical periods of development seen in childhood, when the brain is especially receptive to reorganization.
Physical Safety and Toxicity
Classic psychedelics have an unusual safety profile compared to most drugs: their physically lethal dose is extraordinarily high relative to their active dose. For psilocybin, animal studies placed the lethal dose at 275 mg/kg or higher, hundreds of times above what any human would consume. For LSD, the estimated lethal dose has been placed at 100,000 micrograms, roughly 400 times the highest dose used in clinical settings. A systematic review of the toxicology literature noted that the lethal doses of many psychedelics remain effectively unknown because fatal overdoses are so rare. It’s virtually impossible to die from an overdose of psilocybin mushrooms or LSD in practical terms.
That does not mean psychedelics are without risk. The dangers are primarily psychological rather than physiological. Intense fear, panic, paranoia, and disorientation during a trip can lead to dangerous behavior, especially in uncontrolled environments. Reported deaths involving LSD have been linked to violent incidents and unsafe circumstances during the experience, not to the drug’s direct toxicity. Classic psychedelics also show no addiction potential and actually produce rapid tolerance, meaning a second dose taken shortly after the first will have little effect.
One recognized long-term risk is Hallucinogen Persisting Perception Disorder (HPPD), a condition in which visual disturbances from the drug experience, such as trailing images, halos, or visual snow, continue recurring long after the substance has left the body. Estimates place the prevalence at roughly 4% to 4.5% of people with a history of hallucinogen use, with LSD being the most commonly associated substance. Panic disorder, alcohol use disorder, and major depression are the most common conditions seen alongside HPPD.
Clinical Research and Therapeutic Use
Modern clinical trials typically use a fixed dose of 25 mg of synthetic psilocybin as the standard therapeutic dose, with high-dose sessions using 35 mg and some trials exploring supra-therapeutic doses of 50 to 60 mg. These sessions are conducted in controlled settings with trained therapists present before, during, and after the experience.
The FDA granted Breakthrough Therapy Designation to MDMA-assisted therapy for post-traumatic stress disorder in 2017, a status reserved for treatments that show substantial improvement over existing options. Psilocybin has received the same designation for treatment-resistant depression. These designations accelerate the review process but do not guarantee approval. As of now, no psychedelic has received full FDA approval as a prescription medicine.
Legal Status
Under the U.S. Controlled Substances Act, LSD, psilocybin, DMT, and MDMA are all classified as Schedule I substances, the most restrictive category. Schedule I designation means the federal government considers them to have high abuse potential and no currently accepted medical use, though the active clinical research pipeline challenges that second criterion. Several U.S. cities and states have moved to decriminalize possession of certain psychedelics, particularly psilocybin, but federal law still applies. Ketamine is the exception: it is a Schedule III substance and is already legally prescribed for depression through specialized clinics.